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Abstract
Plant breeding has always relied on progress in various scientific disciplines to generate and enable access to genetic vari-
ation. Until the 1970s, available techniques generated mostly random genetic alterations that were subject to a selection 
procedure in the plant material. Recombinant nucleic acid technology, however, started a new era of targeted genetic altera-
tions, or precision breeding, enabling a much more targeted approach to trait management. More recently, developments in 
genome editing are now providing yet more control by enabling alterations at exact locations in the genome. The potential of 
recombinant nucleic acid technology fueled discussions about potentially new associated risks and, starting in the late 1980s, 
biosafety legislation for genetically modified organisms (GMOs) has developed in the European Union. However, the last 
decade has witnessed a lot of discussions as to whether or not genome editing and other precision breeding techniques should 
be encompassed by the EU GMO legislation. A recent ruling from the Court of Justice of the European Union indicated that 
directed mutagenesis techniques should be subject to the provisions of the GMO Directive, essentially putting many precision 
breeding techniques in the same regulatory basket. This review outlines the evolving EU regulatory framework for GMOs 
and discusses some potential routes that the EU may take for the regulation of precision breeding.
The ever expanding plant breeders’ toolbox
Ever since humans started to actively cultivate plants for 
near-settlement access to harvest 12–14,000 years ago, the 
genetic make-up of plants has been altered to better suit 
human needs in terms of cultivation properties and nutri-
tional quality. Starting with the recognition of the Mendelian 
laws of inheritance early in the twentieth century (Fischer 
1936), this breeding process went from a relatively simple 
on-farm mass selection procedure to an active off-farm sci-
entific procedure whereby the variation in the genetic mate-
rial is actively increased and suitable genetic combinations 
are selected for in a much more targeted manner (Smykal 
et al. 2016). The early stages of scientifically guided plant 
breeding involved deliberate crosses between suitable parent 
lines. Later discoveries in physics and chemistry enabled the 
use of mutagenic agents, such as radiation or chemicals, to 
induce random mutations followed by a selection procedure 
of lines with beneficial traits (Ahloowalia and Maluszynski 
2001). Later progress in plant cell and tissue culture also 
allowed wide crosses through protoplast fusion (Glime-
lius 1988), faster hybrid breeding through anther culture 
and double haploid induction (Germaná 2011), and yield 
improvements and wide crosses through polyploidization 
(Sattler et al. 2016). Progress in molecular biology in the 
1960s and 1970s enabled researchers to clone and recombine 
nucleic acid sequences in a highly specific manner, and the 
transfer and incorporation into the genome of novel host 
organisms (Barton et al. 1983; Herrera-Estrella et al. 1983) 
also paved the way for highly controlled and efficient trait 
management. This progress was quickly picked up by the 
commercial seed sector and the first genetically modified 
(GM) crops were commercialized in the early 1990s. More 
recent developments in genome editing (Barabaschi et al. 
2016) have now also enabled mutagenesis to be carried out 
in a targeted way, in contrast to the earlier random mutagen-
esis methods. In other words, modern plant breeding as car-
ried out over the past 120 years is always building on scien-
tific progress in order to expand the available toolbox and 
provide for a more efficient and targeted trait management. 
One striking feature though of the molecular breeding is 
that the genetic alterations, and by extension trait manage-
ment, became much more targeted and specific. Whereas 
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earlier breeding techniques mostly produced random genetic 
alterations, molecular precision breeding allows, whenever 
sequence information is available, specific genes to be pin-
pointed and modified (Moose and Mumm 2008).
EU GMO legislation 1.0: early risk 
management
The products of plant breeding were still in the 1980s by and 
large not subject to any specific requirements for risk assess-
ment. However, the power and utility of recombinant nucleic 
acid technology made scientists voice concerns that these 
versatile techniques could have a potential to be biologically 
hazardous (Rogers 1975), though it was emphasized that the 
concerns were based on judgments of potential rather than 
demonstrated risk (Berg et al. 1974). When the first trans-
genic plants were then produced in the early 1980s (Barton 
et al. 1983; Herrera-Estrella et al. 1983), further discussions 
were triggered about biosafety assessments and regulation 
of the commercial activities within the field of plant genetic 
engineering, and the first biosafety legislation on genetically 
modified organisms (GMOs) was drafted in the European 
Union (EU) in the late 1980s. This resulted in the first Coun-
cil Directive on the deliberate release into the environment 
of GMOs (Directive 90/220/EEC) in 1990 (Official Journal 
of the European Communities 1990). The ensuing procedure 
for risk assessment and risk management of GMOs in the 
EU has thus been established with the purpose of ensuring 
a high level of protection of human health and the environ-
ment. The original intentions when drafting this legislation 
was to allow for an acknowledgment of the potential ben-
efits of the GM techniques, acknowledge their prospective 
history of safe use, allow a periodic updating of annexes to 
accommodate scientific progress, and to progressively shift 
the focus from the techniques to the resulting organisms 
and their traits (Commission of the European Communities 
1988; Eriksson 2018a). However, these original intentions 
did not find their way into the Directive 90/220/EC, and have 
yet to materialize into the implementation of the current EU 
GMO legislation.
EU GMO legislation 2.0: centralization 
and amplification
During the 1990s, a number of food crises affected Europe 
in parallel with ethical discussions surrounding the emer-
gence of mammal cloning technology. The first GM crops 
and their derived products had reached the market in 
Europe, but also the first studies reporting potential health 
risks with the consumption of GM food products appeared 
(Ewen and Pusztai 1999). Voices were therefore raised for 
a higher level of scrutiny and risk assessment of GMOs, 
and a de facto moratorium on the authorizations of novel 
GMOs and their derived products was put into effect in the 
EU in 1998. A process started to reform the GMO legisla-
tion, introducing labeling and post-authorization monitor-
ing requirements (Official Journal of the European Union 
2003b). Most importantly, the entire risk assessment and 
authorization procedure was centralized, whereas Directive 
90/220/EC had left both the risk assessment and the authori-
zation decision in the hands of the individual EU member 
states [though other member states had the right to object 
prior to the actual authorization and, in case of dispute, the 
final decision was left to the European Commission (EC)]. 
The European Food Safety Authority was created to provide 
for a centralized risk assessment and the decision on adop-
tion or rejection was henceforth taken collectively by all 
member states (or ultimately by the European Commission, 
EC) (Official Journal of the European Communities 2001; 
ibid, 2002; Official Journal of the European Union 2003a). 
A number of other details were also introduced, such as a 
limit to the placing on the market to a period of ten years 
after which renewal is required, a public consultation before 
authorization, and in particular a much stronger emphasis 
on the precautionary principle. Regarding the data required 
for the risk assessment, these are not specified in Directive 
2001/18/EC or Regulation 1829/2003, but over the years 
EFSA has published an increasing number of guidelines for 
this purpose. It is now argued that this increasing number of 
EFSA guidelines is creating an unpredictable situation for 
the applicants, given that the handling times are also getting 
progressively longer (EuropaBio 2015). For an excellent and 
detailed description of how the GMO risk assessment in 
the EU has developed over the years, it is recommended to 
read Casacuberta et al. (2017). One problem though with 
the collective decision-making procedure is that the required 
qualified majority is almost never reached (Smart et al. 2015; 
Casacuberta et al. 2017).
Emerging techniques and the need for a new 
approach
Since the revised regulatory framework for GMOs was 
developed in the EU in the early 2000s, there has been con-
siderable progress both in the development of breeding tech-
niques and in our understanding of how naturally dynamic 
the genetic material is. Over the past decade, there has there-
fore been considerable debate on what exactly constitutes 
a GMO within the EU legislative framework, and thus to 
which organisms the provisions of the Directive applies. The 
definition in Directive 2001/18/EC (Article 2(2)) says that 
it is “an organism in which the genetic material has been 
altered in a way that does not occur naturally by mating and/
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or natural recombination”. Annex 1A also says that “Tech-
niques of genetic modification referred to in Article 2(2)
(a) are inter alia: (1) recombinant nucleic acid techniques 
involving the formation of new combinations of genetic 
material” (Official Journal of the European Communities 
2001). It has therefore been argued that the trigger for the 
EU regulation is based on the presence of foreign recombi-
nant nucleic acids in the final product (Voytas and Gao 2014; 
Jones 2015). Other experts have also argued that a combina-
tion of process and product is necessary to define a GMO 
in the EU, given that a number of techniques are specified 
that do or do not lead to GMOs, while at the same time the 
product needs to contain recombinant nucleic acids to be a 
GMO, implying that only “artificially modified” products 
containing recombinant nucleic acids are encompassed by 
the regulations (Sprink et al. 2016; Kahrmann et al. 2017). 
This has been challenged by several green NGOs, who argue 
that the mere use of a certain technique is sufficient to have 
the resulting product regulated as a GMO (Friends of the 
Earth 2016; Greenpeace 2016). The position taken by sev-
eral EU member states, at least as judged from published 
position papers and other material, tend to be that a type of 
recombinant, foreign nucleic acid needs to be present in the 
final product for it to be regulated as a GMO (for a list of 
member state opinions and references, see Eriksson 2018b).
A recent ruling from the Court of Justice of the Euro-
pean Union (CJEU) on the legal status of mutagenesis (case 
C-528/16) gives an indication regarding how the EU GMO 
legal framework may be applied henceforth. This Court rul-
ing stated that the risks linked to the use of new mutagen-
esis techniques (i.e. directed mutagenesis) might prove 
to be similar to those that result from the production and 
release of a transgenic GMO. Excluding these organisms 
from the scope of the GMO Directive would therefore com-
promise the objective, which is to avoid adverse effects on 
human health and the environment, and the exemption that 
applies to the products of conventional (randomly induced) 
mutagenesis should not apply to the products of directed 
and other new mutagenesis techniques (CJEU 2018). This 
article does not discuss the merits of the Court ruling on 
case C-528/16; however, the implications of the ruling will 
be discussed through a few examples below.
The system has earlier been put to the test on a few occa-
sions. The US-based company Cibus has developed an herbi-
cide-tolerant oilseed rape, using an oligonucleotide-directed 
mutagenesis approach, that has been declared outside the 
scope of regulation in the USA and Canada. The company 
asked six EU member states for the regulatory status of this 
event, and all member states confirmed that it should not 
be regulated as GMO. However, the European Commission 
(EC) instructed the member states to not take any interim 
national decisions, while there is still regulatory uncertainty 
at the EU level. Now with the recent ruling on mutagenesis 
from the Court of Justice of the European Union (CJEU), 
it seems indeed likely that the EU will regulate the Cibus 
ODM-oilseed rape as a GMO. Swedish and Finnish research 
groups have also asked their respective National Competent 
Authorities (NCAs) for advice on whether or not specific 
GMO permit is needed for field trials with CRISPR-modi-
fied Arabidopsis plants, to which the NCAs in both countries 
have responded that plants that do not contain foreign DNA 
will not be regulated as GMO. Again, however, it is unlikely 
that this approach will be viable in the light of the CJEU 
mutagenesis ruling. For a more detailed description of the 
oilseed rape and Arabidopsis cases, see Eriksson (2018a, b).
Options to regulate the products of plant 
breeding
Should molecular precision breeding be treated differently 
compared to breeding techniques that induce mostly ran-
dom genetic alterations, in terms of requirements for human 
and/or environmental risk assessment? There is already an 
indication from the interpretation of mutagenesis that the 
CJEU delivered on July 25, 2018. The interpretation implied 
that the products of directed mutagenesis are considered 
sufficiently distinct from the products of randomly induced 
mutagenesis to subject them to provisions of the Directive 
2001/18/EC, including a requirement for pre-authorization 
risk assessment and an authorization procedure, whereas the 
products of randomly induced mutagenesis are exempt from 
the same. As it is the task of the CJEU only to interpret exist-
ing legislation, it is problematic that the EU GMO legisla-
tion apparently allows a reasoning that divides the products 
of mutagenesis into two distinct categories in this way (ran-
dom vs directed). From a general biosafety perspective, it is 
difficult to envisage that products carrying a small amount 
of precisely induced mutations in pre-defined locations (with 
the possibility of few off-target alterations) should be more 
risky than products carrying a large amount of random muta-
tions (with a large amount of off-target alterations).
The first obvious question is therefore if this categoriza-
tion of breeding techniques into “precision” and “conven-
tional” (or “random”) is relevant or necessary? If the answer 
is no, then the following question is whether the products 
of conventional breeding should be more strictly risk regu-
lated, or if the products of precision breeding should be less 
strictly risk regulated? Alternatively, if the best option would 
be to find a middle way? For the reader who wants to know 
more about the off-target effects of different breeding tech-
niques, it is recommended to read Filipecki and Malepszy 
(2006), Schouten and Jacobsen (2007), Batista et al. (2008), 
Zhou et al. (2012), Schnell et al. (2015), Nelson and Gers-
bach (2016), Anderson et al. (2016), Batista et al. (2017) and 
Herman et al. (2017).
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Several models have been proposed for the regulation of 
products resulting from a variation of breeding techniques. 
The Stanford model suggests a trait-based and technique-
independent model where products would be placed into 
different risk categories on a case-by-case basis (Barton 
et al. 1997; Miller 2010; Conko et al. 2016). A recently 
proposed regulatory framework for genome-edited crops 
suggests that five steps should represent the primary guid-
ing principles: (1) unintentional escape, (2) absence of 
foreign sequences, (3) documentation of DNA sequence 
changes at the target site, (4) unintended secondary edit-
ing events, and (5) documentation of the above four points 
(Huang et al. 2016). A much stronger focus on the modi-
fied traits, rather than the technique used, has also been 
suggested (Marchant and Stevens 2015; Ricroch et  al. 
2016). The Norwegian Biotechnology Advisory Board 
has also recently initiated discussions on what should be 
regulated by the Norwegian Gene Technology Act, and 
proposed an approval system where a three-level hierar-
chy based on genetic change determines the amount of 
assessment needed (Norwegian Biotechnology Advisory 
Board 2018).
Conclusion
From the way in which the EU GMO legislation was set 
up and has developed over the years, it is difficult to avoid 
the general conclusion that in the EU products with highly 
specific, targeted and pre-defined, and few off-target, genetic 
alterations (“precision breeding”) are subject to strict, expen-
sive and time-consuming human health and environmental 
risk assessments and an ensuing authorization procedure, 
whereas products with randomly induced, and plenty of off-
target, genetic alterations (“conventional breeding”) are not 
subject to these specific risk assessments or the authoriza-
tion procedure. The above described alternative regulatory 
models are mostly based on the relevance of technique ver-
sus trait, and/or the level (amount) of genetic alteration, and 
to some extent the origin of transferred genetic material. 
To my knowledge though, it has not been discussed in the 
scientific or gray literature whether or not the specificity/
precision versus randomness of the genetic alterations would 
be a relevant factor to consider when setting up the require-
ments for risk assessment of the resulting products of the 
breeding process. This is surprising, given that it seems (as 
shown here above) to be of such prime importance judging 
from how the EU GMO regulatory framework has evolved, 
not the least with the recent CJEU ruling on mutagenesis. 
I therefore suggest that the relevance (or non-relevance) of 
this factor should be more thoroughly researched and dis-
cussed, both from a scientific and from a legal perspective.
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